

# Recruiting to the BSR Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

All registrations (both participants new to the study and those being re-registered to a new cohort) will count towards UK CRN accrual data. **UK CRN ID: 7302.**

Drug	Biologic/Other targeted therapy Naïve?	Other Details
<b>Inflectra</b> (Infliximab)	<b>No*</b> (*does not need to be biologic/other targeted therapy naïve)	Open to new registrations and existing participants who switch to a biosimilar (including a switch from <b>any</b> biologic/targeted therapy).
<b>Remsima</b> (Infliximab)		
<b>Flixabi</b> (Infliximab)		
<b>Benepali</b> (Etanercept)		
<b>Erelzi</b> (Etanercept)		
<b>Rixathon</b> (Rituximab)		
<b>Cimzia</b> (Certolizumab)	<b>No*</b>	Open to new registrations and existing participants who start Cimzia.
<b>Actemra/RoActemra</b> (Tocilizumab)	<b>No*</b>	Open to new registrations and existing participants who start Actemra/RoActemra or Kevzara.
<b>Kevzara</b> (Sarilumab)		
<b>Olumiant</b> (Baricitinib)	<b>No*</b>	Open to new registrations and existing participants who start Olumiant or Xeljanz.
<b>Xeljanz</b> (Tofacitinib)		
<b>Humira</b> (Adalimumab)	<b>Yes</b> Must not have previously received biologic/other targeted therapy	Referred to as the 'Anti-TNF comparison cohort'.
<b>Enbrel</b> (Etanercept)		
<b>Remicade</b> (Infliximab)		

Registration forms available at [www.bsrbr.org](http://www.bsrbr.org)

New participants must be registered with us within approx. 6 months of first dose date. Follow up of all participants continues even if therapy is switched/discontinued.